APM Aptorum Group

Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States

  • Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is launching its flagship fund - Pyrinas US Healthcare Real Estate Fund 1 SP – to acquire and develop co-working space and incubator facilities for the life sciences sector in the United States;
  • Opportunity to invest in one of the most vibrant real estate sectors in the U.S. that is currently not available in most of the Asia Pacific countries. A great geographical and asset class diversification of Asia Pacific real estate investment;
  • Tap into the life sciences sector that generally has one of the highest barriers to entry amongst different industries;
  • Experienced and unique advisory/management team in this specific sector with established operation track record.

Aeneas Capital Limited (“ACL”) and Pyrinas Real Estate Management Limited (“Pyrinas”), based in Hong Kong, is launching a US$120m innovative closed-ended property fund – Pyrinas US Healthcare Real Estate Fund 1 SP – with a geographical focus on selected cities across North America. Supported by the ecosystem of its affiliated company, Aptorum Group (Nasdaq: APM), the fund’s key investment objective is to acquire and redevelop real estate into shared laboratories and incubator facilities for life science sector start-ups, one of the most vibrant sectors in North America. The fund will focus its investments in primarily four North America mandated cities (namely Cambridge, Boston, Houston, and San Francisco in the United States and Toronto in Canada).

This press release features multimedia. View the full release here:

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Mr. Matthew Wong, Chief Executive Officer of Pyrinas, commented, “These cities have been selected in view of several crucial factors that we believe are best positioned to take advantage of the robust growth in the life science industry. The fund will focus on acquisition and development of real estate suitable for the healthcare and life science sector, particularly in operating laboratories with a co-working space model. We are seeing increasingly robust demand for space by life science companies and start-ups, who are encouraged by the rapidly growing venture capital investment market in North America.”

The fund is targeting a launch size of up to US$120 million with a targeted return of 15-19% per annum (Net IRR) over a period of four years with one-year extension. Pyrinas is currently in discussions with a number of institutional investors and collaborative partners.

Together with its affiliated company Aptorum Group Limited (Nasdaq: APM) and Aeneas Capital, the fund also aims to nurture medical research, the development of intellectual property, and collaboration between scientists, researchers, investors, and industry participants; while providing real estate solutions that foster an ecosystem for collegial interactions among industry, investors, government and academia.

The fund is targeted for institutional and professional investors only and subject to restrictions in certain jurisdictions.

About the Group

Pyrinas Real Estate Management Limited (”Pyrinas”), the real estate arm of Aeneas Group and an affiliate of Aptorum Group, was established in 2018. Pyrinas currently is managing two laboratory facilities and one clinic facility in Hong Kong. For more information about Pyrinas, please visit .

Aeneas Group Limited, the parent company of Aeneas Capital Limited (“ACL”), is a multi-disciplinary financial institution with cross border capabilities and technology services. For more information about Aeneas Group Limited, please visit .

Aptorum Group Limited (Nasdaq : APM) is a biopharmaceutical company currently developing a portfolio of therapeutic candidates and medical devices, and is dedicated to developing and commercializing its portfolio of technologies to tackle unmet medical needs observed globally. For more information about Aptorum Group Limited, please visit .

Disclaimer. The information contained in this press release should not be construed as an offer of, or a solicitation for an investment in, securities or any other financial instrument in any jurisdiction.

EN
16/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aptorum Group

 PRESS RELEASE

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”). ALS-4 is a first-in-class small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus (“MRSA”). Upon the completion of ALS-4’s respective Phase I clinical trials in Canada, ALS-4 has been targetin...

 PRESS RELEASE

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting wi...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration (“US FDA”). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients and has also received orphan drug designation previously from the US FDA. The EOP1 meeting was focused on gaining alignment with the US FDA regarding the clinical and reg...

 PRESS RELEASE

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopau...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting commercial launch of NativusWell®, a new dietary supplement supporting women’s health throughout the Menopausal cycles targeting the China market. NativusWell® has commenced collaboration with one of the largest e-commerce platforms in China, JD.com, and NativusWell® is now distributable in China via JD. China ...

 PRESS RELEASE

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareho...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold a special extraordinary meeting of shareholders at the London office 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 10:00 a.m. London Time on February 21, 2023 (5:00 a.m. Eastern Standard Time on February 21, 2023 / 10:00 a.m. Greenwich Mean Time on February...

 PRESS RELEASE

Aptorum Group Announces 1-for-10 Reverse Stock Split

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the “Company”) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company's Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company’s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company’s Class B Ordinary Shares shall ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch